TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01057147
Drug: rebamipide 2% ophthalmic suspension
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Instill one drop in each eye four times daily for 12 weeks.
Study: NCT00430573
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
Study: NCT01506895
Drug: darapladib
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental compound 160 mg dose
Study: NCT00945724
Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weeks 1-15:~* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days~* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle~* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\&5 of R-CHOP~Weeks 18-22:~• Methotrexate 1.5 g/m2 q14 Days x 2~From Week 24:~• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)
Study: NCT01941849
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
Study: NCT00317785
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00317785
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00317785
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00317785
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03367182
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
Study: NCT03367182
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
Study: NCT03367182
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: bevacizumab \[Avastin\] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
Study: NCT00915018
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
Study: NCT00915018
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
Study: NCT00915018
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
Study: NCT02752113
Drug: Empagliflozin and Linagliptin
Normalized name: Empagliflozin and Linagliptin Tablets
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Empagliflozin and Linagliptin
Study: NCT02752113
Drug: Metformin and Insulin sc
Normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin and Insulin sc
Study: NCT04509336
Drug: Orphenadrine
Normalized name: Orphenadrine
DrugBank: Orphenadrine (DB01173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg twice daily
Study: NCT04509336
Drug: Baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
Study: NCT03684707
Drug: Metformin Hcl 500Mg 24Hr Sa Tab
Normalized name: METFORMIN HCL 500MG 24HR SA TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glucophage 500 mg once daily
Study: NCT03318861
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT00951743
Drug: Adaptavir (monomeric DAPTA)
Normalized name: Monoferric
DrugBank: DAPTA (DB16290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day.
Study: NCT03056638
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix monthly for 6 months
Study: NCT02348788
Drug: Artemether-lumefantrine + Primaquine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02348788
Drug: Chloroquine + Primaquine
Normalized name: chloroquine / primaquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02162251
Drug: Donepezil Hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
Study: NCT02838797
Drug: RQ-00000010
Normalized name: RQ-00000004
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered serotonin 4 receptor partial agonist
Study: NCT00277225
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02909335
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~* between 6 and 10 ng / ml during the first 2 months,~* between 5 and 8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12.
Study: NCT02909335
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~* between 6 and 10 ng / ml during the first 2 months,~* between 5-8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12.
Study: NCT02909335
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
Study: NCT02909335
Drug: Prednisolone, Prednisone or Methylprednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
Study: NCT01534442
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
Study: NCT03532802
Drug: Metoprolol Succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~2. week: steady state treatment with the maximum tolerated dose of the 1.week.
Study: NCT04010630
Drug: Sodium bicarbonate infusion
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion.~Bicarbonate infusion recommendations will be as follow: a central line is recommended, infusion will be slow (125-250ml in 30 min, no intravenous push), careful surveillance of metabolic alkalosis, cardiogenic pulmonary edema, kalemia, natremia and calcemia. Repeated arterial blood gases will be suggested to monitor these critically ill patients and physicians will be reinformed of the potential side effects of sodium bicarbonate infusion.
Study: NCT01876290
Drug: Dexamethasone and Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
Study: NCT01876316
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral administration of 400mg of moxifloxacin
Study: NCT00740363
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily sitagliptin. If GFR\>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
Study: NCT00464958
Drug: sublingual tizanidine 12 mg
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
Study: NCT04452214
Drug: CAN04
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT04452214
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT04452214
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT04452214
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT03627884
Drug: Sodium Bicarbonate Catheter Lock Solution
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using Sodium Bicarbonate Catheter Lock Solution
Study: NCT03627884
Drug: Normal Saline Catheter Lock Solution
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using Sodium Bicarbonate Catheter Lock Solution
Study: NCT00001409
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00126256
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00126256
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00126256
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01542489
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study: NCT01542489
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study: NCT03558425
Drug: CKD-381
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT03558425
Drug: D026
Normalized name: BENZALKONIUM CHLORIDE 1 g in 59 g TOPICAL GEL [Trolls 4pack Hand Sanitizer TD0260WA]
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT01450306
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg d-cycloserine, oral, 1 dose
Study: NCT02375971
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as an intravitreal injection
Study: NCT00288626
Drug: Granulocyte-colony stimulating factor (G-CSF) and prednisone
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Growth factor regimen; occurs at study entry
Study: NCT04439474
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.
Study: NCT02821026
Drug: Anti-Thymocyte Globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02821026
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02821026
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02821026
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02821026
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
Study: NCT01020630
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
Study: NCT02348918
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04545008
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Famotidine
Study: NCT04545008
Drug: N-Acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral N-Acetyl Cysteine
Study: NCT02283424
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
Study: NCT02283424
Drug: chemotherapy (Carboplatin and Docetaxel)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: as control group,compared with Icotinib
Study: NCT01227590
Drug: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
DrugBank: Potato (DB10562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
Study: NCT02485262
Drug: Sofosbuvir and simeprevir
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hepatitis C treatment using Direct Acting Agents
Study: NCT00245128
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
Study: NCT01585051
Drug: 25(OH) vitamin D
Normalized name: 1α,25(OH)2D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
Study: NCT00618644
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab 0.5 mg intravitreal injection
Study: NCT00294866
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
Study: NCT00413946
Drug: Recombinant human Erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
Study: NCT00413946
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: three doses of 1.0 ml saline per body weight
Study: NCT00746889
Drug: triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single intraarticular injection of 40 mg of triamcinolone acetonide
Study: NCT00746889
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intraarticular injection of 1 ml of 0.9% saline
Study: NCT04262089
Drug: Pembrolizumab (Keytruda)
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.
Study: NCT06110494
Drug: NaOCl
Normalized name: SODIUM HYPOCHLORITE 0.01 g in 100 mL TOPICAL LIQUID [NaOClean E-Water]
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive a topical treatment through a root canal irrigation needle containing 3% NaOCl for 10 minutes contact time
Study: NCT06110494
Drug: NaCl
Normalized name: NaCl
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants receive a topical treatment through a root canal irrigation needle containing 0.89% NaCl for 10 minutes contact time
Study: NCT03095326
Drug: Sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo of sucrose syrup
Study: NCT03289026
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Doses were flexibly titrated to between 10 and 30 mg once daily based on the individual needs of the patient as determined by the investigator.
Study: NCT02289248
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will undergo a twice weekly two week course of IV infusions of ketamine
Study: NCT00105079
Drug: saquinavir [Invirase]
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 milligram (mg) Oral (po) twice daily (bid)
Study: NCT00105079
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir 400/100 mg po bid
Study: NCT00105079
Drug: Emtricitabine/tenofovir disoproxil fumarate
Normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
Study: NCT00105079
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg po bid
Study: NCT02536079
Drug: NeuroAiD
Normalized name: lidocaine hydrochloride Topical Cream [Neuromed]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02148978
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
Study: NCT01186003
Drug: Detemir
Normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
Study: NCT02183883
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.~EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade \> 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg.